Treatments in Phase 2 Trials


Name: ABY-035/AFO2
Indication: Psoriasis

  • Affibody
  • IL-17A inhibitor

Name: M1095/ALX-0761
Indication: Psoriasis

  • Merck
  • IL-17A and IL-17F inhibitor

Name: Namilumab (MT203)
Indication: Psoriasis

  • Takeda
  • Granulocyte macrophage colony stimulating factor antagonist

Name: SHR-1314
Indication: Psoriasis

  • Jiangsu HengRui Medicine Co., Ltd.
  • IL-17A Antagonist

Name: Tildrakizumab (MK-3222/SCH 900222/SUNPG1623)
Indication: PsA

  • Merck and Sun Pharma
  • IL-23 inhibitor
  • Approved to treat psoriasis

Oral Treatments

Name: Apo805K1
Indication: Psoriasis

  • ApoPharma

Name: BI 730357
Indication: Psoriasis

  • Boehringer Ingelheim
  • Nuclear Receptor Antagonist

Name: FP187
Indication: Psoriasis

  • Forward-Pharma
  • Fumaric acid

Name: JTE-451
Indication: Psoriasis

  • Akros Pharma Inc.
  • RORγ Antagonist

Name: KD025 (SLx-2119)
Indication: Psoriasis

  • Kadmon Corporation
  • ROCK2 inhibitor

Name: Orismilast (UNI50001)

Indication: Psoriasis

  • UNION Therapeutics
  • PDE4-inhibitor

Name: PF-06826647
Indication: Psoriasis

  • Pfizer
  • TYK2 Inhibitor

Name: Prurisol
Indication: Psoriasis

  • Cellceutix Corporation
  • IL-20 and PRINS inhibitor

Name: XP23829
Indication: Psoriasis

  • Dr. Reddy’s Laboratories and XenoPort
  • Fumaric acid

Name: ZPL-389
Indication: Psoriasis

  • Ziarco Pharma Ltd.
  • Histamine H4 receptor antagonist


Name: Roflumilast (ARQ-154) foam
Indication: Scalp Psoriasis

  • Arcutis Biotherapeutics
  • PDE4 Enzyme Inhibitor

Name: EISO (SAN021)
Indication: Psoriasis

  • Santalis Pharmaceutical, Inc.
  • PDE4 blocker

Name: Eucrisa (crisaborole/AN2728)
Indication: Psoriasis

  • Pfizer
  • Phosphodiesterase-4 inhibitor
  • Approved for atopic dermatitis

Name: LAS41004
Indication: Psoriasis

  • Almirall/Aqua
  • Bexarotene/betamethasone dipropionate

Name: PF-06700841
Indication: Psoriasis and PsA

  • Pfizer
  • JAK1 and TYK2 inhibitor

Name: PH-10
Indication: Psoriasis

  • Provectus Biopharmaceuticals
  • Rose Bengal

Name: SNA-120 (CT 327/pegcantratinib)
Indication: Psoriasis

  • Sienna Biopharmaceuticals/Creabilis SA
  • TrkA kinase blocker

Stay in the Know.

Expert tips, can’t-miss events and the latest news, straight to your inbox.

National Health Council Standards of ExcellenceCharity NavigatorCommunity Health Charities logoTwill Care logo

Copyright © 1996-2022 National Psoriasis Foundation/USA

Duplication, rebroadcast, republication or other use of content appearing on this website is prohibited without written permission of the National Psoriasis Foundation (NPF).

NPF does not endorse or accept any responsibility for the content of external websites.

NPF does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.